Evidence map›Paper›PMID 36980573›Full record

ArticleCancers2023

Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer.

Iktej Singh Jabbal, Saad Sabbagh, Mira Itani, Barbara Dominguez, Mohamed Mohanna, Valencia Henry, Hong Liang, Diana Saravia, Tiffany George, Zeina Nahleh and 2 more

Full text read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Iktej Singh JabbalDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.ORCID 0000-0001-8991-7445
Saad SabbaghDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.ORCID 0000-0001-5203-1050
Mira ItaniDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.ORCID 0000-0003-1703-6811
Barbara DominguezDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.ORCID 0000-0001-7618-4545
Mohamed MohannaDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Valencia HenryOMS-II, Edward Via College of Osteopathic Medicine-Carolinas Campus, Spartanburg, SC 29303, USA.
Hong LiangDepartment of Clinical Research, Cleveland Clinic Florida, Weston, FL 33331, USA.
Diana SaraviaDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Tiffany GeorgeDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Zeina NahlehDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Evan AlleyDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Rafael Arteta-BulosDepartment of Hematology/Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Disparities in cancer treatment and outcomes have long been well-documented in the medical literature. With the eruption of advances in new treatment modalities, the long-existing disparities are now being further uncovered and brought to the attention of the medical community. While social health determinants have previously been linked to treatment disparities in lung cancer, we analyzed data from the National Cancer Database to explore sociodemographic and geographic factors related to accepting or declining physician-recommended chemotherapy. Patients diagnosed with metastatic lung cancer between 2004 and 2016 who declined chemotherapy recommended by their physicians were included in this study. Multivariate logistic regression analysis was performed. Cox Regression and Kaplan-Meier analyses were performed to look for survival characteristics. (2) Results: 316,826 patients with Stage IV lung cancer were identified. Factors related to a higher rate of refusal by patients included older age > 70, female sex, low income, lack of insurance coverage, residency in the New England region, and higher comorbidity. Patients living in areas with lower education were less likely to decline chemotherapy. (3) Conclusion: Further understanding of the factors impacting treatment decisions would be essential to improve the efficacy of care delivery in patients with cancer and reduce reversible causes of disparity.

Indexed as

chemotherapydisparities in cancer carelung cancerrefusal of treatment

Identifiers

PMID36980573
PMCPMC10046757

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read49
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.